Clinical Trials Logo

Delusional Disorder clinical trials

View clinical trials related to Delusional Disorder.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT04874974 Completed - Schizophrenia Clinical Trials

Feasibility of a Novel Process-based Treatment for Patients With Psychosis

PROBAS
Start date: May 10, 2021
Phase: N/A
Study type: Interventional

The purpose of this single-arm feasibility study is to develop and pilot test a novel process-based and modular group therapy approach for patients with acute psychotic symptoms in an inpatient setting.

NCT ID: NCT04783285 Completed - Schizophrenia Clinical Trials

Effect of Individual Cognitive Stimulation at Home in Adults With Psychotic Disorders

Start date: March 29, 2021
Phase: N/A
Study type: Interventional

The aim of this study is to test the effect of cognitive stimulation (CS), applied individually and at home, on the overall cognitive functioning, emotional state, functionality, and quality of life (QoL) in adults with psychotic disorders. To this end, a randomised controlled clinical trial will be conducted in which selected participants will be randomly assigned to an individual intervention group using CS or a control group. The CS program is adapted from other existing protocol, composed of 32 sessions. Each session will last 45 minutes and will be held twice weekly. There will be four evaluation points (baseline, intra-evaluation - after 8 weeks of intervention, post-evaluation - after 16 weeks of intervention, follow-up - after 8 weeks of the end of intervention).

NCT ID: NCT03559426 Completed - Schizophrenia Clinical Trials

Research Into Antipsychotic Discontinuation and Reduction Trial

Start date: March 24, 2016
Phase: Phase 4
Study type: Interventional

Psychosis and schizophrenia are common and costly mental health problems. Psychosis is the name given to a group of mental conditions in which cause people to perceive or interpret things differently from those around them. One of the most common causes of psychosis is schizophrenia, a condition that causes a range of psychological symptoms, including hallucinations (hearing and/or seeing things) and delusions (believing something that is not true). One of the main treatment options for psychosis and schizophrenia is long-term treatment with antipsychotic medication, but many patients still find life difficult. Antipsychotic drugs can also have dangerous and unpleasant side effects. Finding alternatives to long-term drug treatment is a priority for patients and services. This study is testing the effects of gradually reducing antipsychotic medication in people with schizophrenia, psychosis or similar conditions in order to see if it can help improve day-to-day functioning and how it affects their chance of suffering a relapse (worsening of their condition).

NCT ID: NCT02787122 Completed - Schizophrenia Clinical Trials

Pilot-trial of Emotion-focused Cognitive Behavior Therapy for Patients With Schizophrenia

CBT-E
Start date: January 1, 2014
Phase: N/A
Study type: Interventional

The present study is a pilot single-blind randomized controlled therapy study. Its aim is to assess the efficacy of an emotion-focussed form of Cognitive behavior Therapy that focusses on emotional processes that are involved in the formation and maintenance of delusions such as emotional stability, emotion regulation and self-esteem.

NCT ID: NCT01981759 Completed - Schizophrenia Clinical Trials

D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions

Start date: February 2014
Phase: Phase 4
Study type: Interventional

This study is a placebo-controlled 12 week trial of DCS augmentation of once-weekly CBT sessions in 60 schizophrenia subjects with antipsychotic-resistant delusions. In addition to testing efficacy, this trial will characterize DCS effects in terms of time course and persistence of response and will examine DCS effects on memory consolidation and cognitive flexibility as possible mediators of DCS enhancement of CBT for delusions.

NCT ID: NCT01822418 Completed - Schizophrenia Clinical Trials

Agomelatine Treatment of Depression in Schizophrenia (AGOPSYCH)

AGOPSYCH
Start date: January 2013
Phase: Phase 4
Study type: Interventional

Major depressive episodes (MDEs) occur frequently during the course of psychotic disorders, and several antidepressive agents have been successfully applied. The new melatonergic antidepressant agomelatine (AGO) appears promising for the treatment of MDEs in schizophrenia for several reasons. The investigators plan to test the efficacy and tolerability of AGO for antidepressive treatment in schizophrenia. For this task, the investigators plan to enrol 27 schizophrenic patients into an open, single-armed, prospective clinical trial with agomelatine.

NCT ID: NCT01216891 Completed - Schizophrenia Clinical Trials

Multi-disciplinary Treatment for Patients Experiencing First Episode of Psychosis

Start date: October 2010
Phase: N/A
Study type: Interventional

This study will assess the effectiveness of an experimental treatment intervention for adolescents and adults who have experienced their first episode of psychosis during the past two years. The DUP sub-study will collect pathways to care information that will be used to inform the development and pilot testing of strategies that aim to reduce DUP among individuals experiencing a first episode of psychosis.

NCT ID: NCT00716755 Completed - Schizophrenia Clinical Trials

Minimizing Doses of Antipsychotic Medication in Older Patients With Schizophrenia.

Start date: October 2009
Phase: N/A
Study type: Interventional

Since side effects of antipsychotics, dopamine D2 receptor blockers, frequently occur in older patients with schizophrenia and the risk is dose dependent, clinical guidelines universally advocate the use of lower doses. However, there is no report to test this dosing guideline with measurements of D2 receptor blockade caused by antipsychotics. In this study, dopamine D2 receptor occupancy will be measured, using Positron Emission Tomography (PET), in 40 patients aged 50 and older with schizophrenia-spectrum disorders before and after a gradual 40 % dose reduction of antipsychotics that was safely achieved in the past study while setting a target dose still above the lower limit of the dose range recommended in clinical guidelines for older patients. Our goal is to relate changes in clinical outcome, including subjective and objective clinical ratings, to dopamine D2 receptor occupancy, and compare these results with the data for younger patients in the literature.

NCT ID: NCT00657631 Completed - Schizophrenia Clinical Trials

Acceptance and Commitment Therapy for Delusions

ACT
Start date: April 2008
Phase: N/A
Study type: Interventional

Symptoms of schizophrenia have historically been treatment resistant despite advances in psychopharmacology. Acceptance and Commitment Therapy (ACT) has been shown through some preliminary research to be effective with psychotic symptoms (Bach & Hayes, 2002). ACT is considered part of the "third wave of CBT" along with Dialectical Behavior Therapy (DBT; Linehan, 1993) and Mindfulness-based Cognitive Therapy (MBCT; Segal, Williams, & Teasdale, 2001). The target of change in ACT is acceptance of symptoms as experiences that a person can have without experiencing distress, and while living a life in accordance with one's values. The current study assessed the effectiveness of ACT (8 sessions) for delusions. Participants received treatment as usual throughout the study. The intervention followed the protocol of ACT described in Hayes, Strosahl and Wilson (1999) in which treatment will consist of building acceptance, willingness, and commitment to change, clarifying values, defusion of thoughts and feelings, as well as defusion of self. These therapeutic aims attempted to be achieved by the practice of various exercises in and out of session as well as the discussion of various metaphors within session. It was hypothesized that participants will exhibit decreased distress due to delusions, decreased delusional conviction and a reduction of overall anxiety levels from participants' baselines.

NCT ID: NCT00644800 Completed - Schizophrenia Clinical Trials

A Study of the Efficacy and Safety of Intramuscular Ziprasidone Followed by Oral Ziprasidone for the Treatment of Psychosis

Start date: July 2003
Phase: Phase 4
Study type: Interventional

To assess the efficacy, safety, and tolerability of intramuscular ziprasidone in the treatment of the acute exacerbation of non-organic psychosis of any etiology, including schizophrenia, acute mania, delusional disorder and others.